首页> 外文OA文献 >Continuous veno-venous haemofiltration in the treatment of severe acute pancreatitis: 6-year experience
【2h】

Continuous veno-venous haemofiltration in the treatment of severe acute pancreatitis: 6-year experience

机译:连续静脉血液滤过治疗严重急性胰腺炎:6年经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background. Continuous veno-venous haemofiltration (CVVH) could be reasonable for attenuation of systemic complications in severe acute pancreatitis (SAP). The aim of the study was implementation and feasibility assessment of the CVVH in the treatment protocol of SAP. Patients and methods. CVVH was applied to 111 SAP patients during 2000–2005. APACHE II, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), serum lipase, C-reactive protein (CRP), complication rate and main outcomes were analysed comparing two periods. Results. Overall, 39 patients corresponded to Balthazar grade E SAP and 72 patients to necrotizing SAP (NSAP), with an average APACHE II score of 7 and 8.5, respectively, on admission. CVVH was started within 48 h in 82% of patients. Duration of CVVH was significantly augmented in NSAP patients during the routine period, comprising 92 h (p=0.006). The clinical presentation of SIRS and MODS was similar in both periods, with more initial pulmonary dysfunctions in NSAP (p=0.048). Peripancreatic infection decreased in the routine period; surgical interventions were performed in 34.8% vs 72.4% of patients. Hospital stay comprised on average 15.9 days for grade E SAP and 29.4 days for NSAP in the routine period, with overall mortality of 10.26% and 30.5%, respectively. Discussion. Application of CVVH in the treatment protocol of SAP is obscure due to relative invasiveness, a poorly understood mechanism of action and scarce clinical experience. We conclude that early pre-emptive application of CVVH is safe and feasible in the treatment of SAP. Duration of the procedure seems to be essential. Randomized clinical trials are justified. Our results are in favour of clinical application of CVVH in the treatment of SAP.
机译:背景。持续静脉静脉血液滤过(CVVH)对于减轻严重急性胰腺炎(SAP)的系统并发症可能是合理的。该研究的目的是在SAP治疗方案中实施CVVH并进行可行性评估。患者和方法。在2000-2005年期间,将CVVH应用于111位SAP患者。比较两个时期,分析APACHE II,系统性炎症反应综合征(SIRS),多器官功能障碍综合征(MODS),血清脂肪酶,C反应蛋白(CRP),并发症发生率和主要结局。结果。总体而言,入院时39例患者相当于Balthazar E级SAP,72例坏死性SAP(NSAP),平均APACHE II评分分别为7和8.5。 82%的患者在48小时内开始CVVH。在常规期间,NSAP患者的CVVH持续时间显着增加,包括92 h(p = 0.006)。在两个时期中,SIRS和MODS的临床表现均相似,在NSAP中初始肺功能障碍更为严重(p = 0.048)。在常规期间,胰周感染减少; 34.8%的患者接受了手术干预,而72.4%的患者接受了外科手术。在常规期间,E级SAP平均住院时间为15.9天,NSAP平均为29.4天,总死亡率分别为10.26%和30.5%。讨论。 CVVH在SAP的治疗方案中的应用由于相对侵入性,对作用机理的了解不多以及缺乏临床经验而难以理解。我们得出结论,早期抢先使用CVVH在治疗SAP中是安全可行的。该过程的持续时间似乎至关重要。随机临床试验是合理的。我们的结果有利于CVVH在SAP治疗中的临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号